Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Terms of Use
Privacy Policy
Sitemap
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Medical Oncology
GIST
Questions discussed in this category
Would you recommend imatinib 400 mg BID or stay with the usual dose of 400 mg/day for adjuvant therapy for a patient with intermediate-high risk exon 9 mutated GIST?
1 Answer available
How do you treat metastatic, wild-type GIST?
1 Answer available
How do you approach adjuvant therapy for a resected gastric GIST when the risk for recurrence is discordant between various prediction tools?
For example, gastric GIST, < 5 mitoses/hpf and size > 5 cm but < 10 cm is intermediate by NIH criteria but low by NCCN/CAP criteria. Th...
1 Answer available
Outside of a clinical trial, how do you approach upfront therapy for a PDGFRA D842V-mutant GIST?
Would your recommendations change in the neoadjuvant versus adjuvant or metastatic setting?
2 Answers available
How do you approach non-surgical patients with GIST who are intolerant to imatinib 400 mg daily and unlikely to tolerate other TKIs?
Do you reduce the dose to <400 mg daily or employ dosing schedules?
2 Answers available
How do you choose your next line of therapy for stage 4 GIST after progression on imatinib?
How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?
2 Answers available
14932
12598
3765
1870
5837
4464
Papers discussed in this category
JAMA Oncol,
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
The Lancet. Oncology, 2009-11
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
Ann. Surg. Oncol., 2015 Feb 05
Validation of the MSKCC Gastrointestinal Stromal Tumor Nomogram and Comparison with Other Prognostication Systems: Single-Institution Experience with 289 Patients.
Related Topics in Medical Oncology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers